Ocoxin Pets Oral Liquid: Product Profile

Ocoxin Pets is a named branded product for Dogs and cats; manufacturer positioning must be kept separate from independent clinical evidence.

Oral liquid complementary feed; official manufacturer page lists 30 mL and 150 mL. Intended species: Dogs and cats.

Glucosamine from fermentation; maltodextrin; DL-malic acid; sodium propionate; potassium sorbate; zinc sulfate monohydrate; manganese sulfate monohydrate; L-arginine; ascorbic acid; calcium-D-pantothenate; pyridoxine hydrochloride; folic acid; vitamin B12/cyanocobalamin; L-cysteine; glycine; ammoniated glycyrrhizic acid; green-tea extract; cinnamic acid; and flavoring compounds.

Catalysis presents Ocoxin Pets as a complementary feed and nutritional/cellular-support formula for dogs and cats. Regional distributors may use stronger oncology language. The encyclopedia separates those marketing descriptions from evidence that the finished product changes a defined cancer endpoint.

May be discussed only as adjunctive/supportive care within a veterinarian-led plan; it must not replace diagnosis, staging, standard treatment, symptom control, or emergency care.

Define a modest supportive goal, objective review date, adverse-effect plan, and stopping rule with the veterinarian.

Bring the current label, lot, complete ingredient panel, seller and country version, and every medicine and supplement to the treating veterinarian.

The current manufacturer page supplies composition, species, form, storage, and manufacturer instructions. It does not by itself prove tumor control. Product-specific peer-reviewed studies, if cited by commercial pages, require separate appraisal for design, species, cancer type, comparator, outcomes, conflicts, and whether the marketed formula matches the tested version. No broad efficacy conclusion is made here.

Green tea, glycyrrhizic acid, minerals, vitamins, preservatives, amino acids, and flavoring require review in the context of hypertension, electrolyte disease, liver or kidney dysfunction, bleeding risk, poor appetite, pregnancy, and concurrent medicines or supplements. “No side effects described” on a manufacturer page cannot prove zero risk or zero interaction.

No universal compatibility conclusion is made. Review the complete label and individualized treatment plan with the veterinarian.

The manufacturer identifies Ocoxin Pets as a complementary feed for veterinary use, not a veterinary medicinal product. Colombia’s ICA May 2026 animal-food register lists OCOXIN PETS, Catalysis S.L., as a registered supplemental feed for canines and felines (ICA 17613SL). That national feed registration is not global drug approval or proof of anticancer efficacy.

Spain; European Union; United States distributor; Colombia registration

Confirm the country-specific bottle, language, formula, lot, and expiry because product presentations and labels can vary. Track appetite, vomiting, stool, drinking, urination, body weight, energy, skin reactions, and treatment adherence. Use the oncology team’s objective disease and toxicity monitoring; do not substitute a commercial “cellular support” concept for staging or response assessment.